RESPONSE TO PACLITAXEL RELATED TO GENITIC VARIATINS IN MDR1

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。具体目的是评估非索非那定水平作为MDR 1活性和紫杉醇药代动力学预测因子的效用，并将MDR 1等位基因变异的存在与紫杉醇药代动力学相关联。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Specific aims are to evaluate the utility of fexofenadine levals as a predictor of MDR1 activity and paclitaxel pharmacokinetics, and to correlate the presence of allelic variations in MDR1 with paciltaxel pharmacokinetics.